论文部分内容阅读
目的分析乳腺癌患者中人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)与细胞增殖抗原Ki67的表达状态,探讨其与乳腺癌前哨淋巴结转移的关系。方法手术治疗121例乳腺癌患者,术中均行前哨淋巴结活检组织病理;采用免疫组织化学法检测乳腺癌组织中HER-2与Ki67的表达情况;采用HE染色法及免疫组织化学法检测前哨淋巴结转移情况;分析HER-2、Ki67与前哨淋巴结转移的相关性。结果 HER-2与Ki67在乳腺癌组织中阳性率分别为55.37%、71.90%;前哨淋巴结转移率为32.23%(39/121);前哨淋巴结转移与HER-2(r=1.000,P=0.000)及Ki67(r=0.994,P=0.006)阳性表达率呈正相关。结论 HER-2及Ki67表达情况可作为辅助评估前哨淋巴结是否转移的重要因素。
Objective To analyze the expression status of human epidermal growth factor receptor-2 (HER-2) and cell proliferation antigen Ki67 in breast cancer patients and to investigate its relationship with the metastasis of sentinel lymph node in breast cancer. Methods Surgical treatment of 121 cases of breast cancer patients, intraoperative resection of sentinel lymph node biopsy histology; immunohistochemical detection of breast cancer HER-2 and Ki67 expression; HE staining and immunohistochemical detection sentinel lymph node Metastasis; analysis HER-2, Ki67 and sentinel lymph node metastasis. Results The positive rates of HER-2 and Ki67 in breast cancer tissues were 55.37% and 71.90%, respectively. The positive rate of sentinel lymph node metastasis was 32.23% (39/121), and the positive rates of HER-2 and HER-2 (r = 1.000, P = 0.000) And Ki67 (r = 0.994, P = 0.006) positive expression rate was positively correlated. Conclusions The expression of HER-2 and Ki67 can be used as an important factor in evaluating the metastasis of sentinel lymph node.